Efficacy and safety of tolvaptan in rapidly progressing autosomal dominant polycystic kidney disease: a single-center, prospective, single-arm study.

Transl Androl Urol · 2026 · PMC13184211 · PMID 42164351

Europe PMC DOI

hedged sentence

0.1200

closest p · 2.4× alpha

0.1200

boldest claim

The sentences

did not reach statistical significanceP=0.12not close (p > 0.1)

At 3 months, the eHTKV-α − annual change in htTKV was −12.6% (IQR, −41.9%, 8.6%), suggesting an actual kidney volume growth larger than expected, but this did not reach statistical significance (P=0.12).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.